Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the recipient of a significant drop in short interest in April. As of April 30th, there was short interest totaling 36,638 shares, a drop of 38.3% from the April 15th total of 59,393 shares. Based on an average daily trading volume, of 97,175 shares, the short-interest ratio is currently 0.4 days. Currently, 1.4% of the shares of the stock are short sold.

Cyclacel Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ BGMS opened at $0.97 on Tuesday. The firm has a market cap of $5.37 million, a P/E ratio of -0.21 and a beta of -0.49. Cyclacel Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $32.25. The stock has a 50 day moving average price of $0.99.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.